Compare SLBT & PAHC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | SLBT | PAHC |
|---|---|---|
| Founded | N/A | 1946 |
| Country | Taiwan | United States |
| Employees | 20 | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.5B | 1.4B |
| IPO Year | N/A | 2014 |
| Metric | SLBT | PAHC |
|---|---|---|
| Price | $2.65 | $36.33 |
| Analyst Decision | | Hold |
| Analyst Count | 0 | 4 |
| Target Price | N/A | ★ $41.25 |
| AVG Volume (30 Days) | 145.3K | ★ 241.2K |
| Earning Date | N/A | 05-06-2026 |
| Dividend Yield | N/A | ★ 0.91% |
| EPS Growth | N/A | ★ 1883.33 |
| EPS | N/A | ★ 1.90 |
| Revenue | N/A | ★ $833,350,000.00 |
| Revenue This Year | N/A | $17.03 |
| Revenue Next Year | N/A | $3.82 |
| P/E Ratio | ★ N/A | $19.14 |
| Revenue Growth | N/A | ★ 4.12 |
| 52 Week Low | $2.54 | $26.08 |
| 52 Week High | $6.25 | $60.08 |
| Indicator | SLBT | PAHC |
|---|---|---|
| Relative Strength Index (RSI) | 35.84 | 60.54 |
| Support Level | N/A | $30.55 |
| Resistance Level | $4.91 | $42.82 |
| Average True Range (ATR) | 0.37 | 1.22 |
| MACD | -0.14 | 0.41 |
| Stochastic Oscillator | 7.91 | 66.81 |
SL Science Holding Ltd is a biomedical company specialized in developing cellular and gene therapies advancing regenerative medicine and cancer treatment. It utilizes immune stem cells to target cancer and bovine-derived milk exosomes to regenerate damaged tissues, thus potentially offering expansive medical applications for its products. With proprietary technologies such as Armed-T and Gamma Delta T cells, as well as exosome applications in skincare and cancer recovery. It operates in three segments namely Exosome products, CD-19 Armed-T products, and GDT cell therapy products. It derives revenue from Exosome products segment.
Phibro Animal Health Corp operates as a diversified animal health and mineral nutrition company. It develops, manufactures, and markets products for a range of food animals comprising poultry, swine, beef and dairy cattle, and aquaculture. The product portfolio of the company includes animal health products such as antibacterials, anticoccidials, nutritional specialty products and vaccines, and mineral nutrition products. The company operates through three segments, Animal Health, Mineral Nutrition, and Performance Products, of which key revenue is derived from the Animal Health segment which relates to the development, manufacturing, and marketing of antibacterials, nutritional specialty products, and vaccines. The entity sells its products in the U.S. and other international countries.